English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Purpose of study This study aims to identify patient socioeconomic and treating facility factors in mucosal melanoma patients that are associated with access to immunotherapy and its impact on the survival of mucosal melanoma patients. Methods used Using the National Cancer Database (NCDB), patients with mucosal melanoma were identified from 2012–2014. Univariate and multivariate regression models were used to analyse factors including age, gender, socioeconomic status, race, treatment facility, and Charlson-Deyo score and their effects on access to immunotherapy as well as their impact on overall survival. A Kaplan Meier curve and a cox regression analysis were used to compare the effect of immunotherapy on overall survival. Summary of results 704 patients with mucosal melanoma were identified in the NCDB between 2012–2014. Of these patients, 656 subjects were used for multivariate analysis to determine odds ratios for receiving immunotherapy. Median overall survival was 17.2±11.1 months. On multivariate analysis, younger age (age <50 years) was associated with increased odds of receiving immunotherapy (OR: 5.05, CI 95%: 2.17–11.72, p=0.001). The presence of metastatic disease increased the odds of receiving immunotherapy (OR: 2.63, CI 95%: 1.54–4.35, p<0.001). Male gender (HR: 1.5, p=0.007), age less than 50 years (HR: 0.44, p=0.011), and treatment in an academic facility (HR: 1.36, p=0.040) were significantly associated with increased risk of death. Immunotherapy had no effect on risk-adjusted overall survival (HR: 0.88, p=0.713). Conclusions In this large cohort of mucosal melanoma, younger patients with metastatic disease were more likely to undergo immunotherapy. However, treatment with immunotherapy was not associated with the patients’ risk-adjusted overall survival. Treatment in an academic facility and male gender did appear to have a negative impact on overall survival, which warrants future studies.

108 Factors associated with access to immunotherapy and its impact on survival in mucosal melanoma